TrialInvestigational new drugs2018

Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.

Margaret T Kasner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.